Taltz in Combination With Enstilar for Psoriasis

Recruiting now · Phase 4

Conditions studied: Psoriasis

In brief

Enstilar in combination with Taltz for plaque psoriasis.

Key facts

Study ID

NCT04372277

Run by

Psoriasis Treatment Center of Central New Jersey

People needed

25

Starts

2020-04-28

Expected to finish

2021-03-30

Last updated by the study team

2020-05-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female adult ≥ 18 years of age;
• Diagnosis of chronic plaque-type
• Body Surface Area between 3%-8%.
• Patient has been treated with Taltz for a minimum of 24 weeks
• Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.
• Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination
• Able and willing to give written informed consent prior to performance of any study-related procedures.

You may not qualify if…

• ˂3% or >8% BSA
• Patient not receiving Taltz, or receiving Taltz <24 weeks
• Any condition, which would place the subject at unacceptable risk if he/she were to participate in the study.
• Pregnant or breast feeding, or considering becoming pregnant during the study.
• Use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
• Use of oral systemic medications for the treatment of psoriasis within 4 weeks.
• Patient used other topical therapies to treat within 2 weeks of the Baseline Visit.
• Patient received UVB phototherapy within 2 weeks of Baseline.
• Patient received PUVA phototherapy within 4 weeks of Baseline.
• Patient has a known hypersensitivity to the excipients of Enstilar® as stated in the label.

Where it is running

• Psoriasis Treatment Center of Central New Jersey — East Windsor, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.